InMed Pharmaceuticals (NASDAQ:INM) (OTCQX:IMLFF) said it launched B2B (business-to-business) sales of rare cannabinoid delta 9-dominant tetrahydrocannabivarin (d9-THCV) in the health and wellness sector via its subsidiary BayMedica.
"In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product," said Shane Johnson, MD, SVP and General Manager of BayMedica.